[MINIREVIEW] Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics

Min Seok Cho; Sang Yeol Kim; Ki Tae Suk; Byung-Yong Kim

doi:10.1007/s12275-018-8346-2

Articles

Page Path: HOME > J. Microbiol > Volume 56(12); 2018 > Article

Review
[MINIREVIEW] Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics: Min Seok Cho ¹, Sang Yeol Kim ², Ki Tae Suk ², Byung-Yong Kim ¹; Journal of Microbiology 2018;56(12):855-867.
DOI: https://doi.org/10.1007/s12275-018-8346-2
Published online: October 25, 2018

¹ChunLab, Inc., Seoul 06725, Republic of Korea, ²Division of Gastroenterology and Hepatology, College of Medicine, Hallym University, Chuncheon 24253, Republic of Korea¹ChunLab, Inc., Seoul 06725, Republic of Korea, ²Division of Gastroenterology and Hepatology, College of Medicine, Hallym University, Chuncheon 24253, Republic of Korea

Corresponding author: Ki Tae Suk , Tel: +82-2-875-2501;,
Byung-Yong Kim , Tel: +82-2-875-2501;,

Received: 26 June 2018 • Revised: 8 August 2018 • Accepted: 21 August 2018

46 Views
0 Download
27 Web of Science
26 Crossref
31 Scopus

Full Article

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common types of liver diseases worldwide and its incidence continues to increase. NAFLD occurs when the body can no longer effectively store excess energy in the adipose tissue. Despite the increasing prevalence of NAFLD, making lifestyle changes, including increased exercise, is often an elusive goal for patients with NAFLD. The liver directly connects to the gut-gastrointestinal milieu via the portal vein, which are all part of the gut-liver axis. Therefore, the gut-microbiome and microbial products have been actively studied as likely key factors in NAFLD pathophysiology. Hence, dysbiosis of the gut microbiome and therapeutic manipulation of the gut-liver axis are being investigated. Novel therapeutic approaches for modulating gut microbiota through the administration of probiotics, prebiotics, synbiotics, and antibiotics have been proposed with numerous promising initial reports on the effectiveness and clinical applications of these approaches. This review delves into the current evidence on novel therapies that modulate gut microbiota and discusses ongoing clinical trials targeting the gut-liver axis for the management and prevention of NAFLD.

Keywords: NAFLD;gut-liver axis;microbiome;probiotics;prebiotics;synbiotics

Figure & Data

References

Citations

Citations to this article as recorded by

Highland barley β-glucan supplementation attenuated hepatic lipid accumulation in Western diet-induced non-alcoholic fatty liver disease mice by modulating gut microbiota
Huicui Liu, Chenxi Nie, Xinzhong Hu, Juxiu Li
Food & Function.2024; 15(3): 1250. CrossRef
Therapeutic applications of melatonin in disorders related to the gastrointestinal tract and control of appetite
Atousa Moghadam Fard, Pardis Goodarzi, Mehran Mottahedi, Setareh Garousi, Hamed Zadabhari, Mohammad Kalantari Shahijan, Saeedeh Esmaeili, Mohsen Nabi-Afjadi, Bahman Yousefi
Naunyn-Schmiedeberg's Archives of Pharmacology.2024; 397(8): 5335. CrossRef
Bifidobacterium lactis Probio‐M8 prevents nonalcoholic fatty liver disease in high‐fat diet‐fed rats: The potential role in modulating gut microbiota
Wen Fan, Kairui Tang, Yuanjun Deng, Chuiyang Zheng, Maoxing Pan, Dajin Pi, Zheng Liang, Jianwei Zhen, Qinhe Yang, Yupei Zhang
Food Bioengineering.2024; 3(1): 29. CrossRef
Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges
Ernesto Saenz, Nathally Espinosa Montagut, Baohong Wang, Christoph Stein-Thöringer, Kaicen Wang, Honglei Weng, Matthias Ebert, Kai Markus Schneider, Lanjuan Li, Andreas Teufel
Engineering.2024; 40: 51. CrossRef
The gut-liver axis in fatty liver disease: role played by natural products
Zhu Ming, Xie Ruishi, Xu Linyi, Yang Yonggang, Luo Haoming, Lan Xintian
Frontiers in Pharmacology.2024;[Epub] CrossRef
Dietary fiber intake and mortality among survivors of liver cirrhosis: A prospective cohort study
Zahra Hariri, Azita Hekmatdoost, Fereshteh Pashayee-khamene, Sara Karimi, Salehe Ahmadzadeh, Zahra Yari
Heliyon.2023; 9(6): e16170. CrossRef
The Activity of Prebiotics and Probiotics in Hepatogastrointestinal Disorders and Diseases Associated with Metabolic Syndrome
Alicia Rodríguez-Pastén, Nury Pérez-Hernández, Javier Añorve-Morga, Rubén Jiménez-Alvarado, Raquel Cariño-Cortés, Teresa Sosa-Lozada, Eduardo Fernández-Martínez
International Journal of Molecular Sciences.2022; 23(13): 7229. CrossRef
Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht
Frontiers in Neuroscience.2022;[Epub] CrossRef
Multi-Omics Nutritional Approaches Targeting Metabolic-Associated Fatty Liver Disease
Omar Ramos-Lopez
Genes.2022; 13(11): 2142. CrossRef
Construction of two new polyoxometalate complexes and their recyclability in photodegradation of cephalexin and ceftiofur
Qian-Qian Wang, Li-Hui Mao, Da-Xiang Wang, Yan-Mei Ma, Xin-Li Shi, Xi-Hao Tian
Inorganica Chimica Acta.2022; 536: 120902. CrossRef
Gut–Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers
Antonio Gil-Gómez, Paola Brescia, Maria Rescigno, Manuel Romero-Gómez
Seminars in Liver Disease.2021; 41(02): 191. CrossRef
Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
Carolina Castillo-Castro, Alexandro José Martagón-Rosado, Rocio Ortiz-Lopez, Luis Felipe Garrido-Treviño, Melissa Villegas-Albo, Francisco Javier Bosques-Padilla
World Journal of Hepatology.2021; 13(11): 1494. CrossRef
Increased Prevalence of Liver Fibrosis in People Living With Human Immunodeficiency Virus Without Viral Hepatitis Compared to Population Controls
Ditte Marie Kirkegaard-Klitbo, Flemming Bendtsen, Jens Lundgren, Robert J de Knegt, Klaus Fuglsang Kofoed, Susanne Dam Nielsen, Thomas Benfield
The Journal of Infectious Diseases.2021; 224(3): 443. CrossRef
Citrulline supplementation attenuates the development of non-alcoholic steatohepatitis in female mice through mechanisms involving intestinal arginase
Dragana Rajcic, Anja Baumann, Angélica Hernández-Arriaga, Annette Brandt, Anika Nier, Cheng Jun Jin, Victor Sánchez, Finn Jung, Amélia Camarinha-Silva, Ina Bergheim
Redox Biology.2021; 41: 101879. CrossRef
Gut metabolites and inflammation factors in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Xiongfeng Pan, Shi Wu Wen, Atipatsa C. Kaminga, Aizhong Liu
Scientific Reports.2020;[Epub] CrossRef
Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view
Hui-Ting Chen, Hong-Li Huang, Yong-Qiang Li, Hao-Ming Xu, Yong-Jian Zhou
World Journal of Gastroenterology.2020; 26(16): 1901. CrossRef
LactobacillusandPediococcusameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome
Na Young Lee, Sang Jun Yoon, Dae Hee Han, Haripriya Gupta, Gi Soo Youn, Min Jea Shin, Young Lim Ham, Min Jung Kwak, Byung Yong Kim, Jeong Seok Yu, Do Yup Lee, Tae-Sik Park, Si-Hyun Park, Byoung Kook Kim, Hyun Chae Joung, In Suk Choi, Ji Taek Hong, Dong Jo
Gut Microbes.2020; 11(4): 882. CrossRef
Macrophages in the pathophysiology of NAFLD: The role of sex differences
Stefano Ministrini, Fabrizio Montecucco, Amirhossein Sahebkar, Federico Carbone
European Journal of Clinical Investigation.2020;[Epub] CrossRef
IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
Sebastião Mauro Bezerra DUARTE, José Tadeu STEFANO, Denise Siqueira VANNI, Flair José CARRILHO, Claudia Pinto Marques Souza de OLIVEIRA
Arquivos de Gastroenterologia.2019; 56(4): 431. CrossRef
Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH)
Sebastião M.B. Duarte, Jose Tadeu Stefano, Claudia P. Oliveira
Annals of Hepatology.2019; 18(3): 416. CrossRef
Aged garlic extract ameliorates fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance
Toshio Maeda, Satomi Miki, Naoaki Morihara, Yoshiyuki Kagawa
Experimental and Therapeutic Medicine.2019;[Epub] CrossRef
Microbiota and nonalcoholic fatty liver disease
Christelle Knudsen, Audrey M. Neyrinck, Nicolas Lanthier, Nathalie M. Delzenne
Current Opinion in Clinical Nutrition & Metabolic Care.2019; 22(5): 393. CrossRef
Gold Nanoparticles Cure Bacterial Infection with Benefit to Intestinal Microflora
Juanjuan Li, Ruitao Cha, Xiaohui Zhao, Hongbo Guo, Huize Luo, Mingzheng Wang, Fengshan Zhou, Xingyu Jiang
ACS Nano.2019; 13(5): 5002. CrossRef
Role of Gut Microbiota in Hepatocarcinogenesis
Haripriya Gupta, Gi Soo Youn, Min Jea Shin, Ki Tae Suk
Microorganisms.2019; 7(5): 121. CrossRef
The Prenatal Microbiome: A New Player for Human Health
Valeria D’Argenio
High-Throughput.2018; 7(4): 38. CrossRef
Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease
David Porras, Esther Nistal, Susana Martínez-Flórez, Javier González-Gallego, María Victoria García-Mediavilla, Sonia Sánchez-Campos
Frontiers in Physiology.2018;[Epub] CrossRef

Cite this Article

Cite this Article: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

[MINIREVIEW] Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics

J. Microbiol. 2018;56(12):855-867. Published online October 25, 2018

DOI: https://doi.org/10.1007/s12275-018-8346-2

Related articles